All In Biotech

Drug Trial Radar · NCT07846267

Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma

Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-05): A Single-arm, Multi-cohort, Phase 2 Trial

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Oct 1, 2029

Study completion Oct 1, 2029

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of cryoablation combined with Anlotinib plus TQB2868 in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.

Conditions

  • Intrahepatic Cholangiocarcinoma

Interventions

  • AnlotinibDrug

    Anlotinib will be administered 10 mg orally daily for 2 weeks followed by a 1 week untreated recovery phase until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

  • TQB2868 InjectionDrug

    TQB2868 will be administered by IV, 300mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

  • cryoablationProcedure

    Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Anlotinib plus TQB2868 will be administered 1-3 days after cryoablation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: max 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.